BMX Alpha Registry
A post-market registry of the BioMatrix AlphaTM (Cobalt Chromium Biolimus
A9 TM (BA9TM) drug-eluting stent)
BMX Alpha is a prospective, multi-center, registry designed to enrol 400 patients to 12 international centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data collection. Major adverse cardiac events (MACE) results at 9 months will be compared to the results obtained from the BioMatrix FlexTM arm of the LEADERS trial.
Major adverse cardiac events (MACE) in the overall population, defined as composite of cardiac death, myocardial infarction (Q-wave and non-Q-wave), or clinically driven target vessel revascularization (TVR) at 9 months.
UK, Spain, Switzerland, Thailand
CERC Asia Services:
- Clinical trial documentation
- Set-up activities
- eCRF / data management
- Monitoring (Thailand)